~~Official Use Only - Security-Related Information~~

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 65

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated August 8, 2012,
1. St. Mary's Medical Center	3. License number 47-09576-01 is amended in its entirety to read as follows:
2. 2900 First Avenue Huntington, West Virginia 25702-1241	4. Expiration date February 28, 2013
	5. Docket No. 03003388 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
Outside of Scope		

~~Official Use Only - Security-Related Information~~

Information in this record was deleted in accordance with the Freedom of Information Act, Exemptions FOIA/PA 2013-0003

C-14

~~Official Use Only - Security-Related Information~~

NRC FORM 374A	PAGE 2 OF 7 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 47-09576-01
	Docket or Reference Number 03003388
	Amendment No. 65

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
Outside of Scope		
G. Strontium 90	G. Sealed Sources (Tracerlab Model RA-1)	G. 100 millicuries
Outside of Scope		

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B. Any imaging and localization study permitted by 10 CFR 35.200.
C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
E. One source for medical use permitted by 10 CFR 35.600, in a Nucletron Model 105.999 remote afterloader unit. The source activity may not exceed 12 curies at the time of medical use. One source in its shipping container as necessary for replacement of the source in the remote afterloader unit.
F. To be used for sample analysis in compatible gas chromatography devices that have been registered either with the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or with an Agreement State.
G. Strontium 90 in an ophthalmic radiotherapy source for storage only.
H. For permanent brachytherapy in the Sirtex Medical Limited SIR-Spheres® delivery system.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 2900 First Avenue, Huntington, West Virginia.

11. The Radiation Safety Officer for this license is James T. Norweck, M.S., DABR.
12. Licensed material is only authorized for use by, or under the supervision of:

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
47-09576-01

Docket or Reference Number
03003388

Amendment No. 65

A. Individuals permitted to work as an authorized user and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
Paul Dexter Akers, M.D.	35.100; 35.200; 35.300
Mark Jason Akers, M.D.	35.100; 35.200
Marsha S. Anderson, M.D.	35.100; 35.200; oral administration of sodium iodide I-131 for imaging and localization studies
Rodger A. Blake, M.D.	35.100; 35.200; 35.300
Paul Henry Blom, M.D.	35.100; 35.200
Silvestre P. Cansino, M.D.	35.100; 35.200
Peter A. Chirico, M.D.	35.100; 35.200; 35.300
James Allen Cochrane, M.D.	35.100; 35.200; 35.300
Ricky Jack Compton, M.D.	35.100; 35.200; oral administration of sodium iodide I-131 for imaging and localization studies
Jeremy Francis Cuda, M.D.	35.100; 35.200; oral administration of sodium iodide I-131
Robert J. Cure, M.D.	35.100; 35.200; oral administration of sodium iodide I-131
Hans G. Dransfeld, M.D.	35.100; 35.200; 35.300
Joseph Dransfeld, M.D.	35.100; 35.200; oral administration of sodium iodide I-131 for imaging and localization studies
Lee Corey Haikal, M.D.	35.100; 35.200; 35.300
David M. Keadle, M.D.	35.100; 35.200; oral administration of sodium

NRC FORM 374A	PAGE 4 OF 7 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 47-09576-01 Docket or Reference Number 03003388 Amendment No. 65

Authorized Users	Material and Use
	iodide I-131 for imaging and localization studies
Michael V. Korona, Jr., M.D.	35.100; 35.200
Eric Lawrence Leonard, M.D.	35.100; 35.200; oral administration of sodium iodide I-131 for imaging and localization studies
Philip P. Lepanto, M.D.	35.300; 35.400; Iridium-192 for uses in a High Dose Rate Remote Afterloader Unit; Yttrium-90 SIR-Spheres
Donald Lewis, M.D.	35.100; 35.200; 35.300
George J. Linsenmeyer, III, M.D.	35.100; 35.200
Richard E. McWhorter, M.D.	35.100; 35.200; 35.300
Grant Douglas Petty, M.D.	35.100; 35.200
James Milton Reynolds, M.D.	35.100; 35.200
Charles Seigler, M.D.	35.100; 35.200
Sanjeev Sharma, M.D.	35.300; 35.400; Iridium-192 for uses in a High Dose Rate Remote Afterloader Unit; Yttrium-90 SIR-Spheres
William S. Sheils, M.D.	35.100; 35.200; 35.300
Ralph A. Stevens, II, M.D.	35.100; 35.200
Torin P. Walters, M.D.	35.100; 35.200; oral administration of sodium iodide I-131 for imaging and localization studies
James Keith Watson, M.D.	35.100; 35.200
Gabriel Mark Werder, M.D.	35.100; 35.200; oral administration of sodium iodide I-131
Abid Yaqub, M.D.	Oral administration of sodium iodide iodine-131

C. The following individuals are authorized medical physicists as indicated:

Authorized Medical Physicists	Material and Use
M. Douglass Allan, M.S., DABR	Iridium-192 in a High Dose Rate Remote Afterloader Unit for calibrations, spot-checks, and training; Strontium-90 ophthalmic sources for storage only
C. Thomas Brannan, M.S., DABR	Iridium-192 in a High Dose Rate Remote Afterloader Unit for calibrations, spot-checks, and training; Strontium-90 ophthalmic sources for storage only
Joseph Britt Colenda, M.S., DABR	Iridium-192 in a High Dose Rate Remote Afterloader Unit for calibrations, spot-checks, and training; Strontium-90 ophthalmic sources for storage only
James G. Cutlip, M.S.	Iridium-192 in a High Dose Rate Remote Afterloader Unit for calibrations, spot-checks, and training; Strontium-90 ophthalmic sources for storage only

D. The following individuals are authorized users for non-medical uses as indicated:

Users	Material and Use
James Allen Cochrane, M.D.	Nickel-63
Philip P. Lepanto, M.D.	Nickel-63
Richard E. McWhorter, M.D.	Nickel-63

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:

A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed six months or at the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.

NRC FORM 374A	PAGE 6 OF 7 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 47-09576-01 Docket or Reference Number 03003388 Amendment No. 65

B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.

C. Sealed sources need not be tested if they contain only hydrogen-3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.

D. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

E. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.

F. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or by other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.

G. Records of leak test results shall be kept in units of microcuries and shall be maintained for 5 years.

15. The licensee shall conduct a physical inventory every six months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 5 years from the date of each inventory and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.

16. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.

17. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

~~Official Use Only - Security-Related Information~~

NRC FORM 374A	PAGE 7 OF 7 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 47-09576-01 Docket or Reference Number 03003388 Amendment No. 65

18. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26 and the letter dated August 25, 2008. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A.	Letter dated August 29, 2002, except intravascular brachytherapy (IVB)	[ML022460072]
B.	Application and letter dated January 30, 2003, except IVB	[ML030350061]
C.	Letter dated March 3, 2006	[ML060820563]
D.	Letter dated April 5, 2006	[ML061020163]
E.	Letter dated September 15, 2006	[ML062700557]
F.	Letter dated September 18, 2006	[ML062700563]
G.	Letter dated September 29, 2006	[ML062760170]
H.	Letter dated October 25, 2006	[ML063100400]
I.	Letter dated January 8, 2007	[ML070080383]
J.	Letter dated February 12, 2007	[ML070430488]
K.	Letter dated August 25, 2008	[ML082470501]
L.	Letter dated September 26, 2008	[ML082820265]
M.	Letter dated May 18, 2012	[ML12165A556]

For the U.S. Nuclear Regulatory Commission

Date August 23, 2012

By ***Original signed by Penny Lanzisera***

Penny Lanzisera
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406

~~Official Use Only - Security-Related Information~~